Immunomic Therapeutics, the U.S. subsidiary of HLB, has completed the first patient dosing in the Phase 1 clinical trial for 'ITI-9001', a vaccine candidate for the treatment of Japanese cedar pollen allergy.


Immunomic, HLB Subsidiary, Administers First Patient Dose of Allergy Vaccine 'ITI-9001' View original image

According to Immunomic Therapeutics on July 3, the patient is currently under observation without any notable adverse reactions or safety issues following administration. After obtaining approval for the Phase 1 clinical trial plan from the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan last month, the company proceeded to first patient dosing in less than a month, accelerating the pace of clinical development.


This Phase 1 trial is a single-center, randomized, placebo-controlled study targeting adults aged 18 to 65 with Japanese cedar pollen allergy. The study will first assess the safety and tolerability in low-dose and high-dose groups to determine the optimal dose, after which the selected dose group will be compared with the placebo group to evaluate safety and immunogenicity.


ITI-9001 is a next-generation therapeutic vaccine candidate that combines the self-amplifying RNA (saRNA) technology with Immunomic's immune therapy vaccine platform 'UNITE'. The antigen is fused with lysosome-associated membrane protein (LAMP) to enhance antigen presentation efficiency and induce T-cell immune responses, aiming for sustained immune therapeutic effects. By targeting 'CryJ2', the major antigen of Japanese cedar pollen allergy, it modulates immune responses to address the root cause of the disease.


Immunomic Therapeutics plans to develop ITI-9001 as a next-generation immune therapeutic option intended to overcome the limitations of existing allergy treatments and achieve fundamental improvement of the disease.



Donggun Kim, CEO of Immunomic Therapeutics, stated, "ITI-9001 is not just a treatment to alleviate symptoms, but a candidate aimed at regulating immune responses to fundamentally improve the disease itself," adding, "Through this clinical trial, we will confirm the safety and initial efficacy, and accelerate its development as a next-generation allergy immunotherapy."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing